During the 1960s three different research groups reported that passage of wild-type yellow fever (YF) virus [strain Asibi (YF-Asibi)] in HeLa cells resulted in attenuation of the virus for monkeys so that the virus no longer caused viscerotropic disease. We have repeated and extended this observation to analyse the process of attenuation of YF virus during cell culture passage. A large plaque (LP) variant of YF-Asibi virus became attenuated for both monkeys and mice following six serial subcultures in HeLa cells (YF-Asibi-LP HeLa p6). Thus, attenuation was probably due to a genetic change in the virus population rather than to selective enrichment of a pre-existing variant of YFAsibi-LP virus. No evidence was obtained to implicate defective interfering particles in the attenuation process. Comparison of the YF-Asibi-LP viruses before and after passage in HeLa cells, using a panel of envelope protein-reactive monoclonal antibodies (MAbs), showed that MAbs which specifically neutralize YF-Asibi-LP virus, and not YF 17D-204 vaccine virus, also neutralized YF-Asibi-LP HeLa p6. This indicated that the epitopes involved in the biological process of neutralization were not altered during attenuation. However, two MAbs that recognize envelope protein epitopes did distinguish between HeLa-and non-HeLa-passaged YF-Asibi-LP virus. One of these (MAb 117) which is YF wild-typespecific, recognized YF-Asibi-LP virus but not YFAsibi-LP HeLa p6 virus, whereas the other (MAb 411), which is YF vaccine-specific, recognized YF-Asibi-LP HeLa p6 virus but not YF-Asibi-LP virus. These results suggest that antigenic changes in the viral envelope protein may determine the relative virulence or attenuation of YF virus.
Introduction
Yellow fever (YF) virus is the prototype of the family Flaviviridae (Westaway et al., 1985) and is responsible for the disease yellow fever. The wild-type virus is mainly viscerotropic causing liver disease and haemorrhagic fever. Live attenuated vaccines were derived from two distinct origins. French workers in Dakar, Senegal developed the French neurotropic vaccine (YF-FNV) strain from a wild-type isolate [the French viscerotropic virus (YF-FVV)] by 128 serial intracerebral mouse brain passages of YF-FVV (Mathis et al., 1928) . Independently, a second vaccine virus was developed from a different wild-type YF virus (Asibi strain) by serial culture in mouse tissue and subsequently chick embryo tissue, until a variant designated YF-17D was isolated after 176 1" Present address: SGRD-UIV, Virology Division, USAMRIID, Fort Detrick, Frederick, Maryland 21701-5011, U.S. A. passages (Theiler & Smith, 1937) . Two substrains of 17D were developed (known as which are the basis of present-day YF vaccine viruses (reviewed in Barrett, 1987) .
We are interested in investigating the molecular basis of attenuation and virulence of YF virus. Comparison of the nucleotide sequence of YF-Asibi with YF-17D and YF-FVV with YF-FNV would be expected to yield equivocal results, as the large number of passages separating wild-type parent from attenuated variant probably results in many nucleotide changes not associated with attenuation/virulence. The genomes of RNA viruses evolve at a high rate, therefore many nucleotide changes occur as a result of passaging. Rice et al. (1985) and Hahn et al. (1987) have cloned and sequenced the entire genomes of YF-17D-204 and of YF-Asibi respectively. Comparison of the nucleotide sequences of parent and vaccine viruses revealed that although 243 passages separate the two viruses there were only 68 nucleotide (32
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amino acid) differences between the two viruses. Although the nucleotide changes are few (0.63~), those nucleotide changes specifically involved in attenuation and/or virulence remain to be identified.
As an alternative approach to analysing attenuation/ virulence of YF virus we have repeated and extended the observation that passaging of YF-Asibi virus in HeLa cells resulted in the loss of the ability to cause viscerotropic disease in monkeys (Hardy, 1963; Hearn et al., 1965 Hearn et al., , 1966 Converse et al., 1971) . Reduced virulence was seen after a single passage in HeLa cells and as few as six passages were required to make YF-Asibi virus avirulent for monkeys [0-04 compared to >700000 mouse intracerebral (i.c.) LDs0 units/LDs0 in monkeys (Hearn et al., 1966) ]. We have repeated these experiments and using monoclonal antibodies (MAbs), have identified changes in the viral envelope protein that may be related to virus virulence.
Methods
Virus. Wild-type YF-Asibi virus had been passed six times in monkeys and twice in mosquito C6/36 cells prior to use in these studies. A seed pool for experiments was prepared by passaging the virus once in stickling mouse brain. A virus with large plaque (LP) morphology was selected by plaque purifying twice in Vero cells, and then amplified twice in LLC-MK2 cells. This virus was termed YF-Asibi-LP. YF-17D-204 was prepared by passaging Connaught Laboratories commercial vaccine (batch number 2837) once in suckling mouse brain.
Passaging of virus in HeLa cells. Subconfluent monolayers of HeLa $2 cells were infected with YF-Asibi or YF-Asibi-LP at a multiplicity of 5. After 1 h incubation at 37°C the inoculum was removed, the monolayer washed once with phosphate-buffered saline (PBS), and MEM containing 2% (v/v) foetal calf serum was added to the culture. Neutral pH of the culture was maintained by addition of 2 M-sodium hydroxide. After 4 days incubation at 37 °C the culture medium was harvested, cell debris removed by centrifugation, and the virus was stored at -70 °C. The same procedure was used to passage the two viruses five more times in HeLa cells except that the incubation period was 3 days from passage 3 onwards.
Plaque assays. Infectivity titrations were performed by plaque assays on Vero cell monolayers, incorporating 0-4% DEAE~lextran into the agar overlay. After 7 days incubation at 37 °C plaques were visualized by staining the monolayers with neutral red.
Monkey studies. Studies were performed in monkeys as described by Monath et al. (1981) MAbs. MAbs used in these studies were described by Schlesinger et al. (1983) , Gould et al. (1985) and Barrett et al. (1990) and were used as ascitic fluids. For indirect immunofluorescence (IIF) experiments SWl3 or HeLa cell monolayers were infected at a multiplicity of 5. After 2 days incubation at 37 °C, the cells were trypsinized and transferred to multispot slides. After 4 h incubation at 37 °C the cells were fixed in ice-cold acetone. For IIF analysis, MAbs were diluted 1 : 100 in PBS and incubated with fixed cells for 30 min at 37 °C. After washing the slides in PBS, fluorescein isothiocyanate-linked antimouse IgG or IgM (diluted 1 : 50 in PBS) was added and incubated for 30 min at 37 °C. Plaque reduction neutralization tests were calculated as serum neutralization indices and performed as described by .
Results

Passaging of YF-Asibi virus in HeLa cells
The YF-Asibi parent virus (which contains a mixture of virions giving large and small plaque morphologies) was used to infect HeLa $2 cells as described in Methods. As seen in Table 1 (left-hand column), no c.p.e, was observed until passage 4; however, infectious virus was produced during each passage. In plaque assays the YFAsibi parent virus population contained predominantly virions of small morphology (90% of population) whereas the viruses isolated after one passage in HeLa cells were predominantly (80 to 90%) LP in morphology. This plaque morphology was maintained during subsequent passage in HeLa cells. As it was probable that a variant had been selected by passage in HeLa cells, we derived a twice plaque-purified LP clone of YF-Asibi virus (YF-Asibi-LP) in Vero cells (Table 1 , right-hand column). As with the parent YF-Asibi virus, the LP clone produced infectious virus in HeLa cells in the absence of c.p.e.; however, c.p.e, was observed at passage 3, one passage earlier than seen previously.
Inoculation of monkeys with YF-Asibi-LP-HeLa p6
Virulence of the virus obtained after six passages of YFAsibi-LP in HeLa cells (YF-Asibi-LP-HeLa p6) was compared to that of the non-HeLa-passaged YF-Asibi-LP virus in cynomolgus monkeys (Table 2) . One monkey was inoculated subcutaneously with 900 p.f.u, of YF- t ND, Not determined. ALT, Serum alanine aminotransferase (normal activity 6-2 to 47-3 units/ml). § PT, Prothrombin time (normally 11 to 13 s). ~> 5-9 NA * Average survival time in days using an inoculum of 100 Vero TCID50. t yx, Not applicable. :~ Scattered deaths (20 to 50~ mortality ratios) using inocula of 103.9 to 106.9 p.f.u.
Asibi-LP while another received 300 p.f.u, of YF-Asibi-LP-HeLa p6. The monkey receiving YF-Asibi-LP died 7 days after infection whereas the monkey receiving YFAsibi-LP-HeLa p6 remained healthy throughout the entire experiment. The latter monkey had a transient viraemia between days 3 and 5 post-infection (p.i.) that was 200 000-fold less than that seen in the monkey which received YF-Asibi-LP. Comparison of liver enzyme levels (aspartate aminotransferase and alanine transferase) revealed transient increases in AST and ALT in the YF-Asibi-LP-HeLa p6 virus-infected monkey on days 5 and 6 p.i., but these were much less than the elevated levels seen in the monkey infected with YF-Asibi-LP virus. The prothrombin time, a more severe test of hepatic dysfunction, remained normal for the monkey infected with YF-Asibi-LP-HeLa p6 virus.
Inoculation of mice with YF-Asibi-LP-HeLa p6
The neurovirulence and neuroinvasiveness of YF-Asibi-LP and YF-Asibi-LP-HeLa p6 for suckling (2 to 4 days old) and weanling (3 to 4 weeks old) mice were compared (Table 3) . YF-Asibi-LP was lethal for suckling mice following i.c. or i.p. inoculation and for weanling mice following i.c. inoculation. YF-Asibi-LP-HeLa p6 was neurovirulent for suckling and weanling mice following i.c. inoculation but weanling mice showed a prolonged survival time (11-6 days) compared to mice inoculated i.c. with YF-Asibi-LP (9-2 days). YF-Asibi-LP-HeLa p6 virus demonstrated reduced neuroinvasiveness and caused only sporadic deaths over a wide dose range following i.p. inoculation of suckling mice. Viraemia was demonstrated in suckling mice following i.p. inoculation of YF-Asibi-LP and the virus invaded the central nervous system by day 4 p.i. In contrast, there was no detectable neuroinvasion following i.p. inoculation of YF-Asibi-LP-HeLa p6 and viraemia occurred late on day 7 (Fig. 1) .
Absence of detectable defective interfering particles in YFAsibi-LP-HeLa p6
Yield reduction assays (Barrett et al., 1984) were used to determine whether or not defective interfering particles played a role in the attenuation process. Three monolayers of HeLa cells were infected with either YF-Asibi-LP. YF-Asibi-LP-HeLa p6 or both at a multiplicity of 5. After 3 days incubation at 37 °C the supernatants were harvested and assayed for infectivity. No difference in infectivity levels between the three samples was observed (data not shown).
Reaction of YF-Asibi-LP-HeLa p6 with neutralizing MAbs
A number of MAbs have been shown to distinguish wildtype YF strain Asibi from its attenuated 17D vaccine derivative in neutralization tests (Schlesinger et al., 1983) . Twelve such MAbs were used to compare YFAsibi-LP-HeLa p6 with YF-Asibi-LP and YF-17D-204 (Connaught Laboratories) vaccine in plaque reduction. neutralization tests and the results were expressed as serum neutralization indices (Table 4 ). All of the MAbs neutralized the YF-Asibi-LP and YF-Asibi-LP-HeLa p6 viruses, albeit at different titres, but none neutralized YF-17D-204. The large differences in neutralization titres between the two Asibi viruses indicate changes in envelope protein epitope(s). In addition, MAb 2El0, which neutralizes all strains of YF virus, was included as a control to demonstrate that YF-17D-204 could be neutralized.
Reactions of non-neutralizing MAbs with YF-Asibi-LPHeLa p6
The virus strains YF-Asibi-LP-HeLa p6, YF-Asibi-LP and YF-17D-204 were examined by IIF tests with a panel of 37 YF envelope protein-reactive MAbs that had been described previously (Schlesinger et al., 1983; (Schlesinger et al., 1983; Gould et al., 1985 Gould et al., , 1989 ., 1985, 1989) of which 33 did not distinguish between the viruses (data not shown). However, four strainspecific MAbs did distinguish between the virus strains ( Table 5) . Two of these MAbs were YF-17D-204 • substrain-specific, one was YF vaccine (i.e. 17D-204, 17DD and YF-FNV)-specific and one was YF wild-typespecific. The two 17D-204 strain-specific MAbs (864 and 8A3) recognized YF-17D-204-USA but not YF-Asibi-LP nor YF-Asibi-LP-HeLa p6 whereas the YF wild-typespecific MAb (117) 
Discussion
In the 1960s it was reported that wild-type YF strain Asibi could be attenuated by passage in HeLa cells (Hardy, 1963; Hearn et al., 1965 Hearn et al., , 1966 Converse et al., 1971) . Attenuation was seen as decreased viscerotropic (i.e. liver) disease in virus-infected monkeys, the natural host of YF virus. Reduced virulence for monkeys was observed after one passage in HeLa cells, and after six passages YF-Asibi virus virulence for monkeys was markedly reduced (> 700000 p.f.u./LD50).
We have repeated the above experiments by passaging YF-Asibi virus six times in HeLa cells. The YF-Asibi virus used for these experiments had received a total of only nine passages (six in monkeys, two in C6/36 cells and once in suckling mouse brain) prior to use in these studies. In plaque assays the virus population consisted of a mixture giving both large and small plaque morphologies. Although the parent virus consisted predominantly of small plaque virions, after one passage in HeLa cells the virus was predominantly of LP morphology. This characteristic was maintained throughout the six passages in HeLa cells. It was unclear whether the attenuation process took place via selection of an attenuated variant in the YF-Asibi population and/or via a genetic change in the YF-Asibi virus. This question was addressed by plaque-purifying a large plaque from the YF-Asibi population twice and passaging this virus (YF-Asibi-LP) six times in HeLa cells (YFAsibi-LP-HeLa p6). The YF-Asibi-LP strain was virulent for the cynomolgus monkey following subcutaneous inoculation whereas the YF-Asibi-LP-HeLa p6 strain was not. This difference in virulence was probably not due to the different challenge doses used (Table 2) because one of us (T.P.M.) has observed that as few as 50 p.f.u, of YF-Asibi virus will kill a cynomolgus monkey following subcutaneous inoculation (T. P. Monath, unpublished observations). Therefore, attenuation of YF virus by passage in HeLa cells probably occurred as the result of a genetic change in the virus gnd selective enrichment of this attenuated variant; however we cannot exclude the possibility that plaque purification of YF-Asibi virus in Veto cells generated a mutant from the LP population. If attenuation by HeLa cell passages results in a genetic change in the virus, very few nucleotide changes may be responsible because so few passages in HeLa cells are required to attenuate YF virus for monkeys. This would be in agreement with the nucleotide sequencing studies of Strauss, Rice, Hahn and coworkers who reported that only 68 nucleotide (and 32 amino acid) differences separate wild-type YF strain Asibi from its 17D-204 live attenuated vaccine derivative (Rice et al., 1985; Hahn et al., 1987) . Examination of the HeLa-passaged viruses in mice showed that the attenuated variant was biologically similar to the attenuated vaccine variant, 17D, described by Theiler & Smith (1937) , in that it showed reduced neuroinvasiveness after i.p. inoculation of suckling mice. It should be noted that 17D was produced by passage of the YF-Asibi virus in chick embryo tissue and required 176 passages before attenuation was observed. The analysis of the two 17D substrain (17D-204)-specific MAbs (Table 5) suggests that we have not recreated the equivalent of 17D-204 and probably not 17D by the HeLa cell passage as MAb neutralization results showed that YF-Asibi-LP and YF-Asibi-LP-HeLa p6 were similar to each other but different from YF-17D-204 (Table 4) . It is also of interest that, in addition to the attenuation for monkeys and mice demonstrated above, Miller & Adkins (1988) have shown recently that the same YF-Asibi-HeLa p6 virus as used in these studies has also lost its mosquito competence and become attenuated for mosquitoes. Thus, only a few passages in HeLa cells are required to alter radically the biological properties of YF virus.
Twelve MAbs that specifically neutralize YF-Asibi-LP and not YF-17D-204 also neutralized YF-Asibi-LPHeLa p6. Hahn et al. (1987) reported that 15 of the 68 nucleotide (12 of the 32 amino acid) differences between YF-Asibi and YF-17D-204 viruses were located in the envelope protein gene. These substitutions undoubtedly account for the change in biological function of epitopes on the envelope protein as observed in neutralization tests. However, YF-Asibi-LP and YF-Asibi-LP-HeLa p6 were similar to each other antigenicaUy and both were distinguishable from YF-17D-204 in neutralization tests. This suggests that nucleotide/amino acid differences reported by Hahn et al. (1987) , while altering neutralizing epitopes, may not be associated with attenuation/virulence of YF virus. However, seven of the 12 neutralizing MAbs tested showed 50-to 630-fold decreases in neutralization titre against YF-Asibi-LP-HeLa p6 virus relative to titres against YF-Asibi-LP virus (Table 4 ). These differences in susceptibility to neutralization may result from mutation affecting neutralization epitopes. If
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so, this would suggest that the attenuation of 17D-204 virus and the loss of neutralization epitopes, as recognized by the neutralizing MAbs used in this study, results from the synergistic effects of more than one amino acid mutation in the envelope protein of 17D-204 virus.
Of the two envelope protein-reactive MAbs which distinguish YF-Asibi-LP-from YF-Asibi-LP-HeLa p6 virus in IIF tests, one was YF wild-type-specific (MAb 117; Gould et al., 1989) and recognized the former but not the latter virus. The other MAb was YF vaccinespecific (MAb 411 ; Gould et al., 1985) reacting with YF 17D-204, 17DD and YF-FNV viruses as well as YFAsibi-LP-HeLa p6, but not YF-Asibi-LP virus. Thus, at least one epitope on the envelope protein has been lost and another gained during passage of the YF-Asibi virus in HeLa cells. Whether or not these two epitopes are functionally or physically linked in some way is not known. The acquisition of the epitope recognized by MAb 411 seems to have a significance in determining attenuation since attenuated variants derived by three different processes have all acquired this epitope. These processes are passage of the wild-type YF-FVV through mouse brain to produce the attenuated YF-FNV (Mathis et al., 1928) , passage of the wild-type Asibi virus through chick embryo tissue to produce the attenuated 17D vaccine virus (Theiler & Smith, 1937) , and passage of Asibi virus through HeLa cells as described in this paper.
Alternatively, loss of the wild-type epitope recognized by MAb 117 during the three attenuation processes may be important. Further studies are necessary to investigate what role, if any, alteration in these envelope protein epitopes plays in the attenuation of YF virus. Studies are now underway to determine the exact location and nucleotide sequence of these envelope protein epitopes.
